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Some patients infected with human immunodeficiency virus (HIV) who are experiencing
antiretroviral treatment failure have persistent improvement in CD4+ T cell counts despite
high plasma viremia. To explore the mechanisms responsible for this phenomenon, 2 param-
eters influencing the dynamics of CD4+ T cells were evaluated: death of mature CD4+ T cells
and replenishment of the CD4+ T cell pool by the thymus. The improvement in CD4+ T cells
observed in patients with treatment failure was not correlated with spontaneous, Fas li-
gand–induced, or activation-induced T cell death. In contrast, a significant correlation between
the improvement in CD4+ T cell counts and thymic output, as assessed by measurement of
T cell receptor excision circles, was observed. These observations suggest that increased thymic
output contributes to the dissociation between CD4+ T cell counts and viremia in patients
failing antiretroviral therapy and support a model in which drug-resistant HIV strains may
have reduced replication rates and pathogenicity in the thymus.
Treatment of patients infected with human immunodeficiency
virus type 1 (HIV-1), using a combination of antiretroviral drugs
that includes a protease inhibitor, leads to a rapid decrease in
virus load and an improvement in the absolute number of cir-
culating CD41 T cells. In a proportion of individuals, however,
virus load either fails to decline or rapidly rebounds after treat-
ment with combined antiretroviral agents. Despite this apparent
treatment failure, some, but not all, of the patients have sub-
stantial and persistent improvement in their CD41 T cell counts,
so-called discordant responses [1–3].
The mechanisms responsible for discordant treatment re-
sponses are not well understood. Two recent studies evaluating
patients with persistently detectable plasma viral mRNA after
treatment have found that the reduction in virus load from
pretreatment levels correlated with the improvement in CD41
T cell counts [4, 5]. A decrease in virus load, however, is not
the only factor explaining discordant responses, because, for
any given reduction in virus load, a wide range of improvement
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in CD41 T cell counts can be observed, and some patients
develop discordant responses despite no reduction or actual
increases in plasma virus load.
A variety of processes have been identified that may con-
tribute to T cell depletion in HIV infection, including the direct
cytopathic effect of the virus [6], the elimination of infected
cells by the immune response [7], virus-induced apoptosis of
uninfected cells [8, 9], induction of abnormalities in cell traf-
ficking [10], and impairment of the generation of T cells within
the thymus [11–13]. Demonstrating the involvement of >1 of
these pathways in the paradoxical increase in circulating CD41
T cells in patients with virologic treatment failure would directly
support the conclusion that the given mechanism has a real
impact on T cell depletion in the course of HIV infection. At
present, however, no information is available concerning the
contribution of changes in these pathways to the improvement
in CD41 T cell counts in patients with discordant responses.
To explore this question, we identified a cohort of patients who,
after being treated for the first time with a protease inhibitor
in conjunction with 2 reverse-transcriptase inhibitors, experi-
enced confirmed virologic failure. In these patients we evaluated
(1) spontaneous and activation-induced death of cultured pe-
ripheral blood lymphocytes and (2) thymic output, as assessed
by quantification of T cell receptor excision circles.
Patients and Methods
Study participants. The group of patients with virologic treat-
ment failure consisted of 18 adult patients followed up at Hoˆpital
Bichat-Claude Bernard who met the following criteria: (1) the pa-
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tient had been treated with a protease inhibitor for the first time
in combination with >2 reverse-transcriptase inhibitors; (2) plasma
HIV RNA levels had been measured before initiating therapy with
the protease inhibitor; (3) treatment with protease inhibitors had
been continued for >1 year after virologic treatment failure had
become evident; and (4) on the day of evaluation, plasma HIV
RNA had returned to levels of >104 copies/mL and had rebounded
to within 1 log10 of the pretreatment levels or was higher than
pretreatment levels. All patients in our cohort who were identified
as meeting the inclusion criteria were evaluated. Initial CD4 T cell
counts or changes in CD4 T cell counts were not used as criteria
for inclusion. These patients (all men) had a age ofmean 5 SD
years.41 5 9
Twelve HIV-1–infected patients who had never received antire-
troviral therapy were evaluated. These patients (8 men and 4
women) had an average age of years. On the day of eval-41 5 13
uation, CD41 T cell counts were cells/L (range,6305 5 214 3 10
cells/L), and virus load was log10 copies/
617–619 3 10 4.5 5 1.1
mL (range, !2.3–6.4 log10 copies/mL). Twelve healthy volunteers
not infected by HIV served as controls. These individuals (4 men
and 8 women) had an average age of years. Informed con-36 5 9
sent was obtained from all participants.
Evaluation of cell death. Mononuclear cells were isolated from
peripheral blood mononuclear cells (PBMC) by centrifugation on
Ficoll-Paque (Pharmacia). Cells were resuspended at cells/61 3 10
mL in complete medium (RPMI-1640 containing 25 mM HEPES,
10% fetal calf serum, 2 mM glutamine, 200 U/mL penicillin G, and
250 mg/mL streptomycin) and 0.5-mL aliquots cultured in 5-mL
polypropylene culture tubes (Falcon 2005, Becton Dickinson). To
test the sensitivity of T cells to death induced by cross-linking
receptors of the tumor necrosis factor (TNF) receptor family, cells
were cultured with 100 ng/mL (final concentration) of fusion pro-
teins containing the extracellular domain of the corresponding cog-
nate ligand linked to a Flag epitope (FasL-Flag, TRAIL-Flag
TNF-a–Flag, or TWEAK-Flag) in the presence of 2 mg/mL anti-
Flag monoclonal antibody (M2, Sigma) [14]. To evaluate activa-
tion-induced cell death, 4 mg/mL activating anti-CD3 monoclonal
antibody (Beckman-Coulter) was added. Cultures were maintained
at 377C in 95% air/5% CO2. Samples were evaluated either before
or after 48 h of culture. The cells were resuspended, and 100-mL
aliquots were removed and were incubated at 47C for 45 min with
fluorescein isothiocyanate (FITC)–conjugated anti-CD4, phyco-
erythrin-conjugated anti-CD8, and PC5-conjugated anti-CD14
monoclonal antibodies, using the concentrations suggested by the
manufacturer (Beckman Coulter). Fifty microliters of Flow-Count
Fluorospheres (Coulter) was added, and the samples were analyzed
by cytometry (FACScan, Becton-Dickinson). Debris was excluded
during acquisition, and 50,000 total events were evaluated. The
number of events corresponding to viable CD41 T cells, viable
CD81 T cells, and fluorospheres was determined by setting appro-
priate gates, and, by use of this information, the total number of
viable CD41 and CD81 T cells remaining in the culture at the time
of analysis was calculated.
Cells in gates used to identify viable CD41 and CD81 T cells
contained !1% positive cells after incubation with FITC-conju-
gated Annexin V (Beckman Coulter). Incubation of Jurkat cells
with the fusion proteins containing the extracellular domain of Fas-
ligand or TRAIL under the conditions used in these experiments
led to massive apoptosis after 24 h of culture (data not shown).
The fusion proteins containing the extracellular domains of TNF-
a and TWEAK have been shown elsewhere to induce apoptosis in
WEHI-164 fibrosarcoma cells and interferon-g–treated HT29 colon
carcinoma cells, respectively, in the presence or absence of anti-
FLAG antibody [14].
Evaluation of thymic output. To evaluate thymic output, T cell
receptor excision circles (TRECs) were quantified, using a modi-
fication of the approach described by Douek et al. [15]. TRECs
are episomal DNA circles formed as by-products of the rearrange-
ment of the T cell receptor locus during T cell development. In this
study, the “signal-joint” TREC, a TREC formed in 70% of all T
cells expressing abTCR, which results from recombination between
the dRec and wJa loci, was evaluated. The percentage of T cells
expressing the CD41 CD45RA1 CD142 “naive” phenotype was
determined by flow cytometry. To measure TRECs, CD41 T cells
were purified from PBMC by using magnetic beads coated with
anti-CD4 monoclonal antibodies (CD4 Positive Isolation Kit, Dy-
nal), following the manufacturer’s instructions (purity 195%), and
were stored at 2807C. DNA was extracted (QIAamp DNA Blood
Mini Kit, Qiagen), and the number of TRECs was determined by
real-time polymerase chain reaction (PCR). Each reaction con-
tained 13 TaqMan Universal PCR Master Mix, 5 mM MgCl2, and
200 nM of each primer and probe (50 mL final volume): TREC-
F2, 5′-GCAACTCGTGAGAACGGTGA; TREC-R1, 5′-CTTTC-
AACCATGCTGACACCTC; TREC probe, 5′-(6-FAM)-CCGTG-
CCAGCTGCAGGGTTTAGG(Tamra)(phosphate). As an index
of total cells, the number of copies of the albumin gene (ALB;
present in only 2 copies per cell and without pseudogenes) [16] was
determined in parallel reactions, as described above, by use of 200
nM each of the following primers and probe: ALB-F1, 5′-GTGAA-
CAGGCGACCATGCT; ALB-R1, 5′-GCATGGAAGGTGAAT-
GTTTCAG; ALB probe, 5′-(VIC)-TCAGCTCTGGAAGTCGA-
TGAAACATACGTTC(Tamra)(phosphate). For both systems, cy-
cling parameters were as follows: 507C for 2 min and 957C for 10
min, followed by 40 cycles at 957C for 15 s and 587C for 1 min.
In each case, the number of cycles required to reach threshold
fluorescence (Ct) was determined. For quantification of both TREC
and ALB, serial dilutions of DNA extracted from thymic tissue
obtained from a 4-month-old infant were used. The difference in
Ct (DCt) for the amplification of albumin and TREC in this stan-
dard was constant over a 100-fold range of dilution of the template,
which indicates that the 2 amplicons had the same efficiency of
amplification [17]. Thus, by comparing the Y intercept of the stan-
dard curves, the preparation was found to have 37.5 albumin se-
quences per 1 TREC sequence. To calculate TREC/103 CD41
CD45RA1 T cells, the following formula was used: TREC/103
CD41 CD45RA1 T of TREC sequences)/cells p [(1000 3 number
(number of albumin sequences/2)]/[% CD45RA1 CD41 T cells/100].
Each sample was evaluated in duplicate at 3 dilutions of template,
and the values were averaged. To assess the reproducibility of the
technique, the same preparation of DNA from normal PBMC was
evaluated in 15 consecutive experiments and gave values of
TREC/106 cells ( ). TRECs were undetectable234 5 70 mean 5 SD
in T cell lines when this technique was used.
Statistical methods. All results are reported as ,mean 5 SD
unless otherwise indicated. Spontaneous cell death was determined
by comparing the number of viable cells present before and after
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Table 1. Plasma human immunodeficiency virus (type I) RNA levels and circulating CD41 T cell
counts in patients with virologic treatment failure before treatment with a protease inhibitor and on
the day of evaluation.
Patient
Length of
treatment
failure, moa
Viral RNA, log10 copies/mL CD4
1 T cells, cells 3 106/L
Before protease
inhibitor treatment
Day of
evaluation Db
Before protease
inhibitor treatment
Day of
evaluation Db
1 32 5.61 5.01 20.60 45 713 668
2 27 3.14 5.44 2.30 72 462 390
3 27 4.89 4.88 20.01 32 301 269
4 31 5.09 4.64 20.45 107 370 263
5 25 5.21 4.29 20.92 68 301 233
6 31 4.87 4.25 20.62 32 254 222
7 33 5.08 4.33 20.75 5 195 190
8 8 5.05 5.07 0.02 172 350 178
9 27 5.37 4.38 20.99 59 230 171
10 21 3.31 4.13 0.82 50 209 159
11 32 4.96 5.05 0.09 140 271 131
12 34 5.28 5.60 0.32 18 146 128
13 22 5.44 5.63 0.19 34 133 99
14 32 5.19 4.76 20.43 15 96 81
15 32 4.26 5.74 1.48 80 146 66
16 32 5.18 5.43 0.25 110 107 23
17 31 5.79 5.78 20.01 27 19 28
18 29 5.72 5.50 20.22 22 6 216
a Number of months that viral RNA was continuously detectable before evaluation.
b Change between the intiation of therapy and the day of evaluation.
48 h of culture. Cell loss induced by ligands of the TNF family
and activation-induced cell death were determined by comparing
the number of T cells remaining at 48 h in cultures performed
without or with the corresponding ligands or the activating anti-
CD3 monoclonal antibody. Both cell viability and thymic output
were evaluated for 13 patients; for the remaining patients only cell
viability ( ) or thymic output ( ) was studied. Compar-n p 3 n p 2
isons between groups were made by analysis of variance; posttest
comparisons (performed only if ) were made using the Dun-P ! .05
nett multiple comparisons test. Results for HIV-infected and -un-
infected individuals were compared using the Mann-Whitney U
test. Correlations were evaluated by linear regression. For all anal-
yses, was considered significant. To confirm the robustnessP p .05
of conclusions drawn from regression analysis, all analyses were
repeated using the nonparametric Spearman correlation and after
excluding individual outlier points. In no case did these procedures
change the interpretation of the findings.
Results
Clinical characteristics of patients with virologic treatment fail-
ure. We sought to identify factors influencing the extent of
improvement in circulating CD41 T cell counts in HIV-infected
patients with persistently elevated virus loads after antiretro-
viral therapy. To minimize the impact of partial treatment re-
sponses on our results, the study was restricted to patients
whose plasma HIV RNA was >104 copies/mL and had returned
to levels that were within 1 log10 of pretreatment levels or higher
than pretreatment levels.
All patients had been treated with >1 nucleoside analogue
reverse-transcriptase inhibitors before receiving protease inhib-
itors, and all had detectable plasma HIV-1 RNA when therapy
with a protease inhibitor was initiated (ritonavir [ ], in-n p 10
dinavir [ ], saquinavir [ ], or nelfinavir [ ]). Thir-n p 5 n p 2 n p 1
teen patients had an initial decrease of >1 log10 in plasma HIV-
1 RNA after treatment with protease inhibitors, and virus
became undetectable (!200 copies/mL) in 6 patients. Evidence
of virologic treatment failure was apparent within 6 months of
treatment in 17 of 18 patients, and, at the time of evaluation,
plasma HIV-1 RNA had been continuously detectable for 12
years in 16 of 18 patients (table 1; mean, months). Dur-28 5 6
ing the year before evaluation, virus load was fairly stable in
these individuals, even in patients for whom therapeutic
changes were made (mean change in virus load in the 12 months
before evaluation: log10 copies/mL).20.2 5 0.6
The evolution of virus load and absolute CD41 T cell counts
between the initiation of therapy and the time of evaluation
are shown in table 1. On the day of evaluation, mean virus
load was log10 copies/mL; the average change since5.0 5 0.6
initiation of therapy was log10 copies/mL (range,10.03 5 0.8
0.99 to 12.3 log10 copies/mL). Before treatment with protease
inhibitors, CD41 T cell counts were generally low (60 5
CD41 T cells/L) and were ! cells/L in 14 of6 646 3 10 100 3 10
18 patients. After therapy with protease inhibitors, CD41 T cell
counts increased in most patients despite virologic treatment
failure. At the time of evaluation, the average increase in CD41
T cells was 1 cells/L, and CD41 T cell counts6179 5 162 3 10
had remained higher than pretreatment values for 15 of 18
patients. Nevertheless, considerable variability in the increase
in CD41 T cell counts was observed (DCD41 T /L:6cells 3 10
2100 to 0, ; 1 to 100, ; 101 to 200, ; 201 ton p 3 n p 3 n p 6
300, ; 1300, .n p 4 n p 2
Loss of cultured T cells. The spontaneous loss of both
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Figure 1. Loss of CD41 and CD81 T cells in culture correlates with virus load but not with improvement in CD41 T cell counts. Peripheral
blood mononuclear cells from patients with virologic treatment failure were cultured for 48 h, and the percentages of CD41 (A and C) and CD81
(B and D) T cells lost during culture were determined. These results were correlated with plasma virus load on the day of evaluation (A and B)
and with the improvement in CD41 T cell counts observed since the initiation of treatment with a protease inhibitor (C and D). No correlation
was observed between the loss of CD41 T cells in culture and the change in CD4 T cells ( ; ). No correlation was found between2r p .06 P 1 .3
the loss of CD81 T cells in culture and the change in CD41 T cells by linear regression ( ; ), when the nonparametric Spearman2r p .08 P 1 0.2
correlation was used ( ; ) or after individual outlier points were excluded.r p 2.32 P 1 .2
CD41 and CD81 T cells during the 48-h culture period was
variable for HIV-infected individuals but, when considered for
the patients as a group, was not significantly different from that
observed for uninfected control subjects ( for both com-P p 0.5
parisons). For patients with virologic treatment failure, the
spontaneous death during culture of CD81 T cells was signif-
icantly greater than that of CD41 T cells ( and26% 5 27%
, respectively; by paired analysis). In these9% 5 14% P ! .002
patients, the spontaneous loss during culture of both CD41 and
CD81 T cells was correlated significantly with virus load (figures
1A, 1B). Most T cells with light scatter properties of dead cells
were stained with annexin V, which suggests that T cell loss
was occurring, at least in part, through apoptotic mechanisms
(data not shown). It is important to note, however, that no
correlation was observed between the spontaneous death during
culture of either CD41 or CD81 T cells and the improvement
in CD41 T cell counts observed in patients with virologic treat-
ment failure (figures 1C, 1D; for both comparisons).P 1 .2
Fas ligand–induced death of both cultured CD41 and CD81
T cells from HIV-infected individuals was significantly in-
creased, compared with that of the corresponding T cell pop-
ulations from uninfected controls (figure 2A). For patients with
virologic treatment failure, the increase in death induced by
culture with Fas ligand over spontaneous cell death was of
similar magnitude for CD41 and CD81 T cells (cell loss induced
by Fas ligand for CD41 cells, ; for CD81 cells,21% 5 19%
; ). As expected, annexin V staining confirmed17% 5 14% P 1 .2
that many of these T cells were dying by apoptosis. There was
no difference, however, in Fas-mediated cell death during cul-
ture between untreated HIV-infected patients and patients with
virologic treatment failure, and the extent of Fas-mediated
death did not correlate with the improvement in CD41 T cell
counts observed in patients with virologic treatment failure (fig-
ure 2B; for both comparisons). Culture of T cells in theP 1 .3
presence of the death-inducing ligands TRAIL, TNF, and
TWEAK did not significantly increase the death of either CD41
or CD81 T cells from HIV-infected or -uninfected individuals
(figure 2A).
For patients with virologic treatment failure, the loss of cul-
tured T cells stimulated through CD3 was increased, compared
with that of unstimulated cells; the magnitude of this effect was
comparable for both CD41 and CD81 T cells ( and8% 5 16%
decreases in cell number, respectively, compared16% 5 15%
with those in unstimulated cultures). Activation-induced cell
death of cultured CD81 T cells from patients with virologic
treatment failure was increased, compared with that of CD81
T cells from uninfected controls ( ). Again, no correlationP ! .05
was observed between activation-induced cell death during cul-
ture of either CD41 or CD81 T cells and the extent of im-
provement in CD41 T cell counts occurring in patients with
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Figure 2. Effect of stimulation of receptors of the tumor necrosis
factor (TNF) receptor family on survival of CD41 T cells in vitro.
Peripheral blood mononuclear cells from uninfected controls (open
bars), patients with virologic treatment failure (solid bars), and human
immunodeficiency virus (HIV)–infected untreated patients (hatched
bars) were cultured for 48 h with fusion proteins containing the ex-
tracellular domain of the indicated ligands linked to a Flag epitope in
the presence of the M2 anti-Flag monoclonal antibody (A). The num-
ber of viable CD41 T cells was determined, and the percentage of
decrease in cell numbers was determined relative to that of parallel
cultures not containing ligands or anti-Flag antibody. M2 indicates
cultures containing the anti-Flag antibody in the absence of ligand.
Results are presented as . For patients with virologic treat-mean 5 SE
ment failure, no correlation was observed by linear regression between
the percentage of decrease in CD41 T cells resulting from culture with
Fas-ligand fusion protein and the change in CD41 T cell counts after
beginning treatment with a protease inhibitor ( ; ), when2r p .01 P 1 .7
the nonparametric Spearman correlation ( ; ) was usedr p 2.05 P 1 .8
or after individual outlier points were excluded (B).
Figure 3. Relationships between the increase in CD41 T cell counts
and T cell receptor excision circle (TREC) levels, virus load, and age.
CD41 T cells were purified from peripheral blood of patients with
virologic treatment failure, DNA was extracted, and TREC/103 CD41
CD45RA1 T cell counts were determined by real-time polymerase chain
reaction. These results were correlated with (A) the improvement in
CD41 T cell counts after beginning treatment with a protease inhibitor
and (B) plasma virus load at the time of evaluation. The relationship
between the improvement in CD41 T cell counts and patient age is
shown in C. NS, not significant.
virologic treatment failure ( for both comparisons; dataP 1 .2
not shown).
Evaluation of TRECs. In vitro studies have shown that
treatment with antiproteases leads to the emergence of viruses
with impaired replicative capacity in the thymus [18], suggesting
that increased regeneration of T cells may contribute to the
increase in CD41 T cell counts occurring in some patients with
virologic treatment failure. To test this hypothesis, dRec/wJa
“signal-joint” TRECs were evaluated in patients with treatment
failure, an approach developed by Douek et al. [15]. As reported
elsewhere, TREC/103 CD41 CD45RA1 T cell counts were lower
in untreated HIV-infected individuals than in uninfected control
subjects, although considerable overlap was observed between
the 2 groups ( [Mann-Whitney U test]; ). Con-U p 23 P ! .05
siderable variability in TREC levels was seen for patients with
virologic treatment failure, but, when the patients were consid-
ered as a group, they were not significantly different from
TREC levels of uninfected control subjects. As shown in figure
3A, however, a significant correlation was observed between
TREC levels and the improvement in CD41 T cell counts
( ; ). In contrast, TREC levels did not correlate2r p .48 P ! .005
with plasma virus load (figure 3B) or with the change in virus
load after antiprotease therapy (data not shown).
Several studies have shown that TREC levels decrease with
age, an observation that we confirmed both for patients with
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virologic treatment failure and for uninfected control subjects
( and , respectively). If TREC levels are directlyP ! .01 P ! .03
linked to increased T cell counts in patients with virologic treat-
ment failure, as suggested by the strong correlation, one would
predict a greater increase in CD41 T cell counts in the younger
individuals. Consistent with this hypothesis, we found that the
increase in CD41 T cell counts in patients with virologic treat-
ment failure was inversely correlated with age (figure 3C).
Discussion
When combined antiretroviral therapy fails to control viral
replication in treated patients, peripheral CD41 T cell counts
can remain paradoxically high, clearly above those recorded
before the initiation of therapy. Although higher CD4 counts
are more common in patients whose plasma viremia remains
below pretherapy levels [4, 5], such “dissociated” response pro-
files are observed in a significant proportion of patients expe-
riencing virologic therapy failure, including individuals whose
virus load returns to pretreatment levels. In this study, we have
examined 2 possible mechanisms for this phenomenon: (1) re-
generation of CD41 T cells by the thymus in spite of high levels
of virus replication and (2) a decrease in spontaneous or in-
duced peripheral CD41 T cell death.
Several authors have suggested that an impairment of thymic
function could contribute to the pathogenesis of HIV-1 infec-
tion [11, 12, 15, 19–21]. Recently, several authors have used the
quantification of TREC in circulating T cells as a surrogate
marker for thymic output, to further evaluate this hypothesis
[15, 22, 23]. Both Douek et al. and Zhang et al. demonstrated
that TREC levels are lower in HIV-infected individuals than
in age-matched uninfected control subjects [15, 22], and Hat-
zakis et al. showed that a progressive decline in the concentra-
tion of TREC is characteristic of patients with progressive dis-
ease [23]. After successful antiretroviral therapy, TREC levels
have been shown to rise in conjunction with CD41 T cells [15],
compatible with the possibility that thymic output can con-
tribute to the restoration of circulating T cells, at least in some
individuals [21, 24]. In our study, we found that TREC levels
were lower in untreated HIV-infected patients than in unin-
fected controls, although considerable overlap in the 2 groups
was observed, as previously described. In patients in whom the
improvement in CD41 T cells occurred despite the persistence
of high levels of circulating virus, we observed a significant
correlation between the improvement in CD41 T cell counts
after treatment and TREC levels.
It is recognized that factors other than thymic output can
affect the TREC:“naive” T cell ratio. In particular, increases
in the proliferation of naive T cells and the reconversion of
“memory” T cells to a naive phenotype [24–27], by increasing
the total number of naive cells, can decrease the TREC:naive
T cell ratio independent of thymic output, and the flux through
these pathways can be increased by stimulation of the immune
system [26, 27]. Thus, in the context of HIV-1 infection, changes
in the extent of virus-induced immune stimulation must be
taken into consideration. For example, when virus load is dra-
matically reduced by effective antiretroviral therapy, the in-
creased proliferation of naive T cells returns toward normal
levels [26] and can produce an increase in the TREC:naive T
cell ratio [27]. Several findings suggest that this was not a con-
founding variable in our study. First, all of our patients had a
persistently high plasma virus load that, on average, was similar
before and after treatment, which suggests that these individuals
were subject to intense, persistent, and relatively constant im-
mune stimulation. The increased sensitivity of T cells from these
patients to Fas ligand–induced cell death is compatible with
the persistence of strong virus-induced immune response (see
below). Second, we observed a fairly strong correlation between
age and both the improvement in CD41 T cell counts and
TREC/103 CD41CD45RA1 T cells in patients with virologic
treatment failure. Thymic output is known to be age dependent
[21, 28], whereas no evidence for age-dependent changes in the
other factors influencing the total size of the naive T cell pool
has been presented. Together, these results suggest that differ-
ences in thymic output explain the variation in the TREC:naive
T cell ratio seen in our patients.
Although the mechanisms through which thymic output may
have been restored in these patients were not directly addressed
by our studies, recent experimental evidence suggests that a
decrease in HIV replicative capacity may be involved. It is now
well established that viruses escaping antiretroviral therapy ac-
cumulate mutations in the reverse transcriptase and/or in the
viral protease that often reduce their overall replicative capacity
[29, 30]. It is interesting to note that the extent of impairment
of viral replication is highly dependent on the nature of the
target cells. In particular, Stoddart et al. have recently shown
that viruses carrying resistant protease sequences from treated
patients replicated almost normally in phytohemagglutinin-
stimulated human PBMC but failed to replicate and to deplete
thymic T cells in thymic implants in SCID-hu Thy/Liv mice
[18]. According to this model, reduced HIV replicative capacity
in thymocytes would improve thymic function, whereas near-
normal viral replication in mature peripheral T cells would
explain the high plasma virus load seen in our patients. Other,
more indirect mechanisms could also contribute to the resto-
ration of thymic function. Cytokines, including interleukin
(IL)–7, are known to be required for thymopoiesis but are also
required for high-level HIV-1 replication in thymocytes [31, 32].
IL-7 levels have recently been found to be negatively correlated
with peripheral CD41 T cell counts in HIV-infected individuals
[33, 34]. Thus, improved thymic output resulting from reduced
HIV-1 fitness in the thymus might further reduce local virus
replication by feedback inhibition of IL-7 production.
Further studies will be required to better define the overall
contribution of improved thymic output to the restoration of
CD41 T cell counts in these patients with discordant responses
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and the mechanisms responsible for this effect. Nevertheless,
we propose that decreased viral replicative capacity due to ac-
cumulated drug resistance mutations, together with adequate
residual thymic function (e.g., younger patients without irre-
versible thymic damage), both contribute to improved CD41
T cell counts through the restoration of thymic output.
In contrast to the findings concerning thymic output, we
found no evidence that a reduction in the death of T cells
contributes to discordant immunovirologic responses. Several
earlier studies quantifying apoptotic cells have shown that the
spontaneous apoptosis of cultured T cells from HIV-infected
individuals is increased compared with that of T cells from
uninfected control subjects, although the effect is generally
smalI (∼2-fold increase), and considerable overlap between
HIV-infected patients and uninfected controls has been found
[9, 35–40]. In this study, the number of viable cells present
before and after 48 h of culture was determined, an approach
that permits the quantification of total cell loss—regardless of
the mechanism—in contrast to earlier studies in which only
relatively intact cells in an early stage of apoptosis were eval-
uated. Using this approach, we did not observe a significant
difference in spontaneous cell death between HIV-infected pa-
tients and uninfected controls. The differences in the techniques
used, the relatively small number of patients evaluated in our
study, and the small number of HIV-infected individuals with
very low CD41 T cell counts—patients who have the highest
levels of spontaneous apoptosis—are possible explanations for
this discrepancy. Consistent with earlier studies, we found that
both CD41 and CD81 T cells from HIV-infected individuals
were considerably more sensitive to Fas ligand–induced apop-
tosis than were T cells from uninfected controls and that ac-
tivation-induced cell death of CD81 T cells from HIV-infected
patients was greater than that of T cells from uninfected control
subjects.
Of particular importance for this study were the observations
that the extent of spontaneous cell death, Fas ligand–induced
cell death, and activation-induced cell death showed no cor-
relation with the improvement in CD41 T cell counts in patients
experiencing virologic treatment failure. Thus, our findings do
not support the idea that the selection of drug-resistant viral
variants changes their propensity to activate pathways, result-
ing in the accelerated elimination of T cells. This is interesting,
because all of our patients were being treated with HIV protease
inhibitors at the time of their evaluation, so our observations
suggest that these antiviral compounds do not by themselves
significantly affect the levels of T cell death, for example,
through a nonspecific inhibitory action on cellular proteases
involved in apoptosis [41].
The mechanisms responsible for accelerated T cell death in
HIV-infected individuals remain controversial. The direct kill-
ing of infected cells by HIV-1 may play a role [6]. In this regard,
we observed a fairly strong correlation between virus load and
spontaneous death of cultured CD41 T cells in the HIV-infected
patients and patients with virologic treatment failure. Against
this possibility, however, we also observed that virus load cor-
related with the spontaneous death of CD81 T cells, that spon-
taneous death was greater for CD81 than for CD41 T cells in
patients with virologic treatment failure, and that activation-
induced apoptosis of CD81, but not CD41, T cells was in-
creased in these patients. These findings better fit the idea that
virus-induced activation of the immune system increases the
number of T cells susceptible to death through apoptotic or
other mechanisms [40]. Our observation that Fas-mediated and
activation-induced cell death remains elevated in patients with
virologic treatment failure offers a possible explanation for the
observation that T cell counts do not return to normal levels
in patients with discordant responses, despite improved thymic
output.
Together, our findings suggest that an improved thymic out-
put may contribute to the restoration of circulating CD41 T
cells seen in some patients with persistently elevated virus loads
after antiretroviral therapy. These results further support the
potential usefulness of therapeutic strategies designed to restore
thymic function in HIV-infected individuals.
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